SCHEMBL16091777

SCHEMBL16091777

CCCc1cc(C)c2scnc2c1N

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NOS2 P35228 3/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GAA P10253 1/20 0.31
▸ NOS3 P29474 2/20 0.31
▸ NOS1 P29475 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ HTT P42858 1/20 0.30
▸ TLR8 Q9NR97 1/20 0.30
▸ TLR7 Q9NYK1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16091768 0.88 KDM4E (0.35) IKBKBALDH1A1KDM4ENOS2NOS3
SCHEMBL15629851 0.87 NOS3 (0.40) ALDH1A1NOS2SMN1; SMN2GAANOS3
SCHEMBL15629819 0.74 NOS3 (0.40) ALDH1A1KDM4ENOS2NOS3NOS1
SCHEMBL15629822 0.73 POLB (0.34) NOS2NOS3NOS1POLBHTT
SCHEMBL16091753 0.70 TERT (0.33) IKBKBALDH1A1KDM4ENOS2SMN1; SMN2
SCHEMBL16091776 0.69 TLR8 (0.34) ALDH1A1KDM4ENOS2NOS3NOS1
SCHEMBL16091767 0.69 NOS2 (0.36) ALDH1A1KDM4ENOS2NOS3NOS1
SCHEMBL16091765 0.68 KDM4E (0.37) IKBKBALDH1A1KDM4ENOS2NOS3
SCHEMBL16091775 0.67 POLB (0.34) NOS2NOS3NOS1POLBHTT
SCHEMBL14282452 0.66 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9340521-B2 Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives GREEN CROSS CORPORATION (KR) 2016-05-17 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES GREEN CROSS CORPORATION (KR) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 IKBKB 1346/4885ALDH1A1 1076/4885KDM4E 1804/4885
US-20140274918-A1 METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES SLC5A2, SLC5A1, SLC10A2 IKBKB 828/4885ALDH1A1 691/4885KDM4E 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback